Kenneth Jay Barr

USPTO Granted Patents = 44 (Patent Applications = 9)

CIPO Patents = 3

EPO Patents = 12 (Patent Applications = 7)

Average Co-Inventor Count = 6.5

ph-index = 16

Forward Citations = 519(Granted Patents)

Location History:

Chicago, IL (US) (2001 - 2004)
San Francisco, CA (US) (2001 - 2011)
Boston, MA (US) (2011 - 2020)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

patents

10 out of 25

Sarcode Bioscience Inc.

Sunesis Pharmaceuticals, Inc.

University of Pittsburgh

patents

7. 3 out of 55

Merck Sharp + Dohme B.v.

patents

8. 3 out of 4,177

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

44 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2020-08-18),

2. 10584121 - Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof (2020-03-10),

3. 10377768 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-08-13),

4. 10221146 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-03-05),

5. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-03-05),

6. 10196354 - 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof (2019-02-05),

7. 10124000 - Modulators of cellular adhesion (2018-11-13),

8. 9884043 - RORgammaT inhibitors (2018-02-06),

9. 9809561 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2017-11-07),

10. 9783511 - Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease (2017-10-10),

11. 9745265 - 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof (2017-08-29),

12. 9663522 - 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof (2017-05-30),

13. 9663502 - 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease (2017-05-30),

14. 9657033 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease (2017-05-23),

15. 9603838 - RORgammaT inhibitors (2017-03-28),

Title: **Innovative Contributions of Kenneth Jay Barr in Patent Law and Pharmaceuticals**

Introduction

Kenneth Jay Barr, based in Boston, MA, has made significant strides in the realm of pharmaceuticals, holding a remarkable total of 44 patents. His innovative work primarily revolves around compounds that inhibit RORgamma activity, showcasing his dedication to advancing treatments for various diseases.

Latest Patents

Kenneth's most recent patents include groundbreaking research on bicyclic compounds and their therapeutic applications. One notable patent details the invention of tetrahydronaphthyridine, benzoxazine, aza-benzoxazine, and related bicyclic compounds, specifically aimed at the inhibition of RORgamma activity for treating diseases. This invention encompasses pharmaceutical compositions that include these compounds or their pharmaceutically acceptable salts, providing a pathway for treating conditions mediated by RORgammaT. Additionally, his work on heteroaryl substituted benzoic acids further contributes to the field by offering compounds that serve as RORgammaT inhibitors for treating related diseases or conditions.

Career Highlights

Throughout his career, Kenneth has been affiliated with prominent companies such as Merck Sharp & Dohme Corporation and Sarcode Bioscience Inc. His experience in these organizations has propelled his innovation and patent development, leading to his current standing as a notable inventor in his field.

Collaborations

Kenneth has collaborated with esteemed coworkers, including Wang Shen and Johan D Oslob. These partnerships have played an essential role in the evolution of his research and the success of his patent applications, reinforcing the importance of teamwork in achieving innovation.

Conclusion

Kenneth Jay Barr stands out as a pivotal figure in the landscape of pharmaceutical inventions and patent law. His substantial portfolio of patents reflects his commitment to enhancing medicine and improving lives through innovative solutions. As research continues to evolve, Kenneth's contributions will undoubtedly remain influential in the ongoing pursuit of scientific advancement.

This text is generated by artificial intelligence and may not be accurate.